Monte Rosa Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
New Enterprise Associates 17, L.P. and affiliated entities have filed an amendment to their Schedule 13D, reporting a beneficial ownership of 7.9% of Monte Rosa Therapeutics, Inc. common stock.
NASDAQ
New Enterprise Associates 17, L.P. and its affiliates reported a decrease in their beneficial ownership of Monte Rosa Therapeutics, Inc. common stock to 9.6% due to an increase in the issuer's outstanding shares.
NASDAQ
Versant Venture Capital and Versant Vantage I have reduced their aggregate beneficial ownership in Monte Rosa Therapeutics, Inc. to 4.99% through a series of stock sales and pro rata distributions.
NASDAQ
Versant Venture Capital VI, L.P. distributed 744,800 shares of Monte Rosa Therapeutics common stock to its limited partners without additional consideration.